ROGERS, Conn. _ Rogers Corp. on Monday reported first-quarter net income of $14.9 million. For the current quarter ending in July, Rogers Corp. expects its per-share earnings to range from 81 cents to 91 cents. Rogers Corp. shares have climbed 14 percent since the beginning of the year.
--Abiomed Inc rescheduled second-quarter conference call to Nov. 1 at 8 am Eastern Time. --Accelrys Inc rescheduled third-quarter results to Oct. 31, after market. Its conference call will be held on Nov. 1, 9.30 am Eastern Time.
--Acorda Therapeutics Inc: rescheduled third-quarter financial results and conference call to Oct. 31 from Oct. 30. --Advent Software Inc reschedules third-quarter results and conference call to Oct. 30. --AGCO Corp rescheduled third-quarter results to Oct 31, 8 am Eastern Time from Oct. 30.
--Martha Stewart Living Omnimedia Inc rescheduled third-quarter results to Nov. 1 from Oct. 30. --Vertex Pharmaceuticals Inc rescheduled third-quarter 2012 earnings and conference call to after markets close on Nov. 1 from Oct. 29. --The McGraw-Hill Companies Inc rescheduled third-quarter earnings and conference call to Nov. 2 from Oct. 31.
*FDA approves expanded indication for Actemra in rheumatoid arthritis. *Genentech-FDA expanded approved indication for actemra for treatment of. adults with moderately to severely rheumatoid arthritis.
ZURICH, Oct 11- Leading drugmakers will help set up psychological centres for victims of child sex abuse in an effort to counter the long-term health problems suffered by victims.
Oct 11- Roche Holding AG:. *Liberum Capital cuts Roche Holding AG to hold rating. Reuters Station users, click. 1580.
Oct 11- Roche Holding AG:. *Credit Suisse raises Roche price target to Sfr 215 from Sfr 180. Reuters Station users, click. 1580.
NEW YORK, Oct 10- Experimental Alzheimer's drugs from Roche Holding AG and Eli Lilly& Co have been selected for a high-profile clinical trial to test whether it is possible to prevent the brain-wasting disease from developing in at-risk patients.
Oct 10- Experimental drugs from Roche Holding AG. and Eli Lilly& Co have been selected for a global Alzheimer's disease prevention trial, and a second Lilly drug is being considered for inclusion in the study, Washington University said on Wednesday.
Oct 10- Roche Holding AG's experimental drug gantenerumab and Eli Lilly& Co's solanezumab have been chosen to be tested in a high-profile global Alzheimer's disease prevention trial, and a second Lilly medicine is being considered for potential inclusion in the study, Washington University said on Wednesday.
alzheimer's prevention trial-- Washington university. in global trial- Washington university. alzheimer's in different way-- Washington university.
NEW YORK, Oct 10- Experimental Alzheimer's drugs from Roche Holding AG and Eli Lilly& Co have been selected for a high-profile clinical trial to test whether it is possible to prevent the brain-wasting disease from ever developing in at-risk patients.
**ARQULE INC, $2.30, down 53.9 pct The biotechnology company and Japan's Daiichi Sankyo Co Ltd. **GENERAL MOTORS, $23.82, up 3 pct. Hedge fund manager David Einhorn said auto-maker General Motors "is much healthier now," and is getting its product refreshments "right."
The Dow and S&P 500 turned negative while the Nasdaq cut its gains in late morning on Tuesday, with materials and energy shares leading declines on the S&P. **ARQULE INC $2.21 down 55.5 pct The biotechnology company and Japan's Daiichi Sankyo Co Ltd. **FORD MOTOR CO, $9.78, down 1.6 pct.
The Nasdaq Composite Index added 14.98 points, or 0.48 percent, to 3,128.51. **ARQULE INC $2.14, down 57.73 pct The biotechnology company and Japan's Daiichi Sankyo Co Ltd. **SIRIUS XM RADIO INC, $2.62, up 2 pct.
LONDON, Oct 1- The results of two studies into Roche's breast cancer drug Herceptin published on Monday showed that the current standard treatment of taking the drug for a year provides the best outcome for patients.
By Kate Kelland LONDON, Oct 1- Extending treatment with Roche's. Analysts had said the Swiss firm, the world's biggest maker of cancer drugs, could lose up to $1.5 billion in revenue from the blockbuster medicine in the medium term if six months treatment had been shown to be just as effective.
*HERA trial favours status quo, PHARE trial inconclusive* Experts say key message is one year of Herceptin is best* Results limit downside risk for Roche's Herceptin revenues By Kate Kelland LONDON, Oct 1- Extending treatment with Roche'S. Data from both trials were presented at the European Society of Medical Oncology conference in Vienna on Monday.
LONDON, Oct 1- Extending treatment with Roche's. breast cancer drug Herceptin to two years from the one year current standard is not worth while, trial data showed on Monday, but shortening treatment to six months also looks unlikely to benefit patients.